Media Articles Related to Jevtana (Cabazitaxel)
Testosterone and Prostate Cancer: Looks Safe But . . . (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2016.09.24]
(MedPage Today) -- Data accumulating but not yet definitive
Data: May Be OK to Give 'T' to Men With Prostate Cancer
Source: Medscape Hematology-Oncology Headlines [2016.09.22]
The idea of prescribing testosterone to men with prostate cancer was once an anathema. But new data from a small patient cohort suggest that it may be okay.
Medscape Medical News
No Vasectomy-Prostate Cancer Link in Largest Study to Date
Source: Medscape Hematology-Oncology Headlines [2016.09.20]
Vasectomy is unlikely to meaningfully increase risk of developing or dying of prostate cancer, according to a new analysis of observational data.
Medscape Medical News
Vasectomy May Not Raise Prostate Cancer Risk After All
Source: MedicineNet Prostate Cancer Specialty [2016.09.20]
Title: Vasectomy May Not Raise Prostate Cancer Risk After All
Category: Health News
Created: 9/19/2016 12:00:00 AM
Last Editorial Review: 9/20/2016 12:00:00 AM
Study: Prostate Cancer-Vasectomy Link Weakens (CME/CE)
Source: MedPage Today Oncology/Hematology [2016.09.19]
(MedPage Today) -- Mortality, incidence, grade all unrelated to procedure
Published Studies Related to Jevtana (Cabazitaxel)
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. [2011.04]
For patients with metastatic castration-resistant prostate cancer (mCRPC), the current standard of care is chemotherapy involving the tubulin-binding taxane docetaxel. However, as the tumor cells become resistant to docetaxel-based therapy, disease progression is inevitable, and until recently there was no further available treatment beyond palliative care.
Cabazitaxel for the second-line treatment of metastatic hormone-refractory
prostate cancer: a NICE single technology appraisal. 
The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of cabazitaxel (Jevtana®, sanofi-aventis, UK) to submit evidence of
its clinical and cost effectiveness for the second-line treatment of metastatic
hormone-refractory prostate cancer (mHRPC)... They concluded that whilst
the clinical effectiveness of cabazitaxel had been proven, it was not likely to
represent a cost-effective use of NHS resources and so its use could not be
Managing side effects of the novel taxane cabazitaxel in castrate-resistant
prostate cancer. 
Cabazitaxel, a novel taxane, was approved in June 2010 by the U.S. Food and Drug
Administration for treatment of metastatic castrate-resistant prostate cancer
(mCRPC) in men previously treated with docetaxel... This article reviews the vital role of nurses in
identifying patients at high risk for AEs associated with cabazitaxel therapy and
reviews strategies for prevention and management of symptoms.
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment
of hormone-refractory metastatic prostate cancer: summary of the scientific
assessment of the committee for medicinal products for human use. 
On March 17, 2011 the European Commission issued a marketing authorization valid
throughout the European Union for Jevtana® (Sanofi-Aventis, Paris, France) for
the treatment of patients with hormone-refractory metastatic prostate cancer
previously treated with a docetaxel-containing regimen... The detailed scientific assessment report and
product information, including the summary of product characteristics, are
available on the European Medicines Agency Web site (http://www.ema.europa.eu).
Cabazitaxel: a novel microtubule inhibitor. [2011.07.09]
The development of drug resistance is a major obstacle to effective cancer therapy. Several agents are in clinical development with the goal of overcoming resistance... This article presents the preliminary antitumour activity, safety, tolerability and pharmacokinetic data of cabazitaxel, and an overview of the current status of clinical development.
Clinical Trials Related to Jevtana (Cabazitaxel)
Cabazitaxel - PF Induction Chemotherapy [Completed]
The primary objective of this study is to determine the first-cycle maximum tolerated dose
(MTD) and recommended Phase II (RP2D) dose of Cabazitaxel when combined with Cisplatin and
Follow-Up induction chemotherapy in patients with locally advanced squamous cell carcinoma
of the head and neck for three cycles.
Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) [Recruiting]
Due to limited experience with cabazitaxel in TCCU, the study will be started as a
randomised phase II study. The aim of the phase II study is to evaluate if the response
rates (CR + PR) are sufficiently high to further study the treatment regimens in a phase III
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer [Withdrawn]
Cabazitaxel is already approved by the Food and Drug Administration (FDA) for use in
patients with advanced prostrate cancer, following docetaxel therapy. The purpose of this
study is to better understand the response and toxicity of cabazitaxel of elderly men (age
75 years and older) with advanced prostate cancer who have progressed during or after
treatment with docetaxel. All patients on this study will receive cabazitaxel by intravenous
(through a vein) infusion plus prednisone by mouth twice daily, and following the
chemotherapy infusions, an injection of a granulocyte colony-stimulating factor (G-CSF).
G-CSF will help the body produce more white blood cells, which should help decrease the risk
of getting an infection while being treated with cabazitaxel.
Study of Weekly Cabazitaxel for Advanced Prostate Cancer [Active, not recruiting]
This is a multicenter open label non randomized phase II clinical trial of Weekly
Cabazitaxel for Advanced Prostate Cancer in Hormone-Refractory Patients Previously Treated
The purpose of this study is to evaluate the activity of the weekly administration of
cabazitaxel as time to progression by PSA at week 12.
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer [Recruiting]
This is a single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel with
concurrent intensity modulated radiation therapy (IMRT) (A type of 3-dimensional radiation
therapy that uses computer-generated images to show the size and shape of the tumor. Thin
beams of radiation of different intensities are aimed at the tumor from many angles.) and
androgen deprivation therapy (Treatment to suppress or block the production or action of
male hormones) in patients with locally advanced prostate cancer.
It is hoped that by adding Cabazitaxel to the standard IMRT, greater local disease control
can be achieved and eventually the cure rate can be increased. After this study, the
maximally tolerated dose of Cabazitaxel that could be used in combination with radiation can
Men with locally advanced high risk prostate cancer represent a group of patients for whom
cure is potentially achievable utilizing a multimodality approach. More aggressive treatment
upfront with chemotherapy and ADT may improve the long term disease control. We hypothesize
that Cabazitaxel may be added to radiation therapy safely, and we anticipate that this novel
approach will improve disease control and eventually improve survival for locally advanced
prostate cancer patients.